<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544711</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0097</org_study_id>
    <nct_id>NCT02544711</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment</brief_title>
  <acronym>MARGIC</acronym>
  <official_title>Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primitive malignant bone tumor or mixt tumor (compounded of soft tissues and bone) is a rare
      pathology particularly within the pelvis, the sacrum or the hip (between 25 and 80 new cases
      in France per year).

      The reference treatment is a surgical &quot;en bloc&quot; resection associated or not to a medical
      treatment. This surgery remains highly challenging because of the complex three-dimensional
      geometry of the pelvic bone and the proximity of important organs and neurovascular
      structures. The local recurrence rate is significantly increased when the resection does not
      respect a safe tissues margin (R0 margin).

      A new technology has been developed and used in different reference sites the Patient
      Specific Instrument (PSI), manufactured by 3D-Side. The PSI allows for a more secure and
      reliable surgical gesture, leading to more frequent R0 margins.

      The main objective of this study is to compare the efficiency of the PSI for bone tumor
      resections within the pelvis with respect to the reference method.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICER between the innovation treatment group and the reference treatment group.</measure>
    <time_frame>3 years</time_frame>
    <description>Incremental Cost-Effectiveness Ratio (ICER) as assessed from the healthcare system perspective: Cost/Local prevented recurrence at 3 years postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0, R1 and R2 margin rates</measure>
    <time_frame>Within 3 years after surgery</time_frame>
    <description>R0, R1 and R2 margin rates as observed by histological exam for each surgical treatment, for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and nature of adverse events related to surgery for each treatment group</measure>
    <time_frame>Per-operatively and within 3 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life (QOL) of patients treated by PSI (prospective group)</measure>
    <time_frame>0, 6, 12, 18, 24, 30 and 36 months</time_frame>
    <description>Euroqol questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect estimations of means of Quality Adjusted Life Years (QALYs) of patients treated by the reference treatment (retrospective group) extrapolated from QOL of patients treated by PSI (prospective group)</measure>
    <time_frame>3 years</time_frame>
    <description>QALYs measures for this group will be extrapolated from the prospective group by estimating the impact of a local recurrence on health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSTS score</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>Musculoskeletal Tumor Society (MSTS) Score which evaluates 6 items: pain, function, emotional acceptance, walking capacity, technical walking aids, gait.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TESS Score</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>Toronto Extremity Salvage Score (TESS) which evaluates 30 items about the global function and patient's activity level.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sarcoma, Bone Tumor</condition>
  <arm_group>
    <arm_group_label>Prospective group :Innovation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical treatment using a patient specific instrument (PSI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective group: Reference</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional surgical treatment without PSI, using 2D imaging planification</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patient specific instrument</intervention_name>
    <description>The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.</description>
    <arm_group_label>Prospective group :Innovation</arm_group_label>
    <other_name>PSI-T</other_name>
    <other_name>3D-Side</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional surgical treatment</intervention_name>
    <description>The conventional treatment is planned on two-dimensional images (CT and MRI).</description>
    <arm_group_label>Retrospective group: Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Critieria:

        Retrospective group (reference)

          -  Patient already operated for the same indication as detailed in the prospective group
             inclusion criteria

          -  Surgery date within the 6 years before the study activation in the participating
             center

          -  Adult (18 years old or more) at the time of surgery

        Inclusion Criteria:

        Prospective group (innovation)

          -  Primitive malignant pelvic bone tumor or mixt tumor (primary bone sarcoma, soft tissue
             sarcoma with bone extension, giant cells tumor of bone and any tumor requiring such a
             resection)

          -  Indication for a wide monobloc resection according to clinical guidelines of the
             pathology (&quot;en bloc&quot; resection of iliac bone including a bone section from
             periacetabular Enneking zone 2 to the sacrum zone 4, hip extra-articular resection for
             proximal femur tumors and sacral tumor or ilio-sacral tumors that need a vertical
             osteotomy or horizontal osteotomy above S2)

          -  Ability to fill in Euroqol and TESS questionnaires

          -  Adult (18 years old or more)

          -  Health insurance holder

        Retrospective group (reference)

        Patient fulfilling the matching criteria with one patient of the prospective group,
        according to the following matching criteria (in order of importance):

          1. Tumor location (Enneking zones 1, 2, 1-2, 2-3, 1-2-3, 1-2-4, 1-2-3-4, 1-4, sacrum)

          2. Tumor type (chondrosarcoma, osteosarcoma, Ewing, chordoma, other tumor type)

          3. Surgery center

          4. Tumor size (as close as possible between both patients)

          5. Response to chemotherapy (good, bad, not applicable).

        Exclusion Criteria:

        Prospective group (innovation)

          -  Patient suffering from a local recurrence or a metastasis at recruitment time

          -  Absence of informed consent

          -  Pregnancy or breastfeeding

          -  Minors

          -  Adults under guardianship or trusteeship

        Retrospective group (reference)

          -  Patient not fulfilling the protocol matching criteria

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Gouin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Gouin, Professor</last_name>
    <phone>+33 2 40 08 48 50</phone>
    <email>francois.gouin@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos MAYNOU</last_name>
      <email>carlos.maynou@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Carlos MAYNOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gualter VAZ</last_name>
      <email>gualter.vaz@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Gualter VAZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon CRCM Les Massues</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gualter VAZ</last_name>
      <email>g.vaz@crcm-massues.com</email>
    </contact>
    <investigator>
      <last_name>Gualter VAZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marseille University Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre ROCHWERGER</last_name>
      <email>richardalexandre.rochwerger@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre ROCHWERGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy Centre Chirurgical Emile Gallé</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François SIRVEAUX</last_name>
      <email>francois.sirveaux@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>François SIRVEAUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Gouin, PhD</last_name>
      <email>francois.gouin@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Juliane Berchoud</last_name>
      <email>juliane.berchoud@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Paris Hospital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ANRACT</last_name>
      <email>philippe.anract@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe ANRACT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris Hospital Kremlin-Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles MISSENARD</last_name>
      <email>missenard.gilles@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles MISSENARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvis</keyword>
  <keyword>Surgical resection</keyword>
  <keyword>Patient specific instrument</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

